BomAH, HeiligersJPC, SaxenaPR, VerdouwPDReduction of cephalic arteriovenous shunting is not mediated by 5-HT1-like or 5-HT2 receptors.Br. J. Pharmacol.1989, 97: 383–390.
2.
SaxenaPR, BomAH, VerdouwPDCharacterization of 5-hydroxytryptamine receptors in the cranial vasculature.Cephalalgia, 1989, 9(Suppl. 9): 15–22.
3.
HumphreyPPA, FeniukW., PerrenMJ, ConnorH, OxfordAWThe pharmacology of the navel 5-HT1-like receptor agonist, GR43175.Cephalalgia, 1989, 9(Suppl. 9):23–33.
4.
Den BoerMO, VillalonCM, HeiligersJPC, HumphreyPPA, SaxenaPRRole of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan.Br. J. Pharmacol.1991, 102: 323–330.
5.
HoyerD, SchoeffterP, GrayJAA comparison of the interactions of dihydroergotamine, ergotamine and GR43175 with 5-HT1 receptor subtypes.Cephalalgia1989, 9: 340–341.
6.
HoyerD., SchoeffterPInteraction of dihydroergotamine (DHE), ergotamine and GR43175 (sumatriptan) with 5-HT1D receptors. Naunya Schmiedeberg's Arch.Pharmacol.1991, 43(Suppl):in press.
